Context Capital Management LLC trimmed its stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) by 50.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 749,605 shares of the company’s stock after selling 750,395 shares during the quarter. Context Capital Management LLC’s holdings in Drugs Made In America Acquisition II were worth $7,631,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kryger Capital LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 1st quarter valued at $3,088,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Drugs Made In America Acquisition II during the 1st quarter valued at $19,960,000. Sona Asset Management US LLC grew its stake in shares of Drugs Made In America Acquisition II by 66.7% during the 1st quarter. Sona Asset Management US LLC now owns 500,000 shares of the company’s stock valued at $4,985,000 after buying an additional 200,000 shares during the period. Wealthspring Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the 3rd quarter worth $4,063,000. Finally, SkyView Investment Advisors LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the 2nd quarter worth $2,515,000.
Analysts Set New Price Targets
A number of research analysts recently weighed in on DMII shares. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. Wall Street Zen upgraded Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Get Our Latest Research Report on Drugs Made In America Acquisition II
Drugs Made In America Acquisition II Stock Up 0.0%
Shares of DMII stock opened at $10.23 on Wednesday. Drugs Made In America Acquisition II Corp. has a fifty-two week low of $9.86 and a fifty-two week high of $10.33. The firm’s 50 day moving average price is $10.18 and its two-hundred day moving average price is $10.08.
Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported $0.07 earnings per share (EPS) for the quarter.
Drugs Made In America Acquisition II Profile
Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.
Read More
- Five stocks we like better than Drugs Made In America Acquisition II
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
